Abstract Background Overcoming the notorious apoptotic resistance of melanoma cells remains a therapeutic challenge given dismal survival of patients with metastatic melanoma. However. recent clinical trials using a BRAF inhibitor revealed encouraging results for patients with advanced BRAF mutant bearing melanoma. but drug resistance accompanied by recovery of phospho-ERK (pERK) acti... https://www.drcristinosuarez.com/